Platinum Diversity: Women, minorities fare worse than white men after PCI
Clinical outcomes for women and minorities after stenting procedures were similar but the rates of death and heart attack were higher in the 1st year, according to the Platinum Diversity study of the Promus Premier everolimus-eluting stent made by Boston Scientific (NYSE:BSX).
The 1-year study enrolled 1,501 women and minorities at 52 U.S. sites and compared their data with a 1,635-patient white male cohort selected from Boston’s Promus Element PAS study.
The combined primary endpoint of death, myocardial infarction and target vessel revascularization was 7.6% for white men but 9.6% for minorities and 8.6% for women. Minorities had the highest rate of death and MI; white men had the highest rate of TVR:
| Minorities | Women | White Men | |
| Death | 3.7% | 3.4% | 2.2% |
| MI | 3.1% | 1.9% | 1.1% |
| TVR | 5.4% | 4.6% | 5.5% |
“This study draws important attention to differences in clinical outcomes after stent implantation in women and minorities,” co-principal investigator Dr. Wayne Batchelor, of Tallahassee’s Southern Medical Group, said in prepared remarks. “The adjusted risk of MI and death/MI was higher in minorities versus white men. In addition, the adjusted risk of death/MI was higher in women than white men with a trend towards higher rates of MI. The similar rates of TVR and stent thrombosis among all 3 groups suggest that ‘stent failure’ is unlikely to account for the observed differences in outcome. Further study into the cause of these observed gradients of risk is necessary to gain insight into the potential impact on clinical practice.”
“The Platinum Diversity trial represents an important example of how we can enrich our understanding of outcomes in the underrepresented population. This is the first trial exclusively enrolling women and minorities undergoing PCI and allows for further evaluation of patients who are usually not represented in clinical studies,” added co-principal investigator Dr. Roxana Mehran of New York City’s Icahn School of Medicine at Mount Sinai.
“The Platinum Diversity study is tangible evidence of the commitment by Boston Scientific to raise awareness of the needs of underserved patient communities across the country, and is a critical first step in advancing care for all patients,” Boston Scientific clinical interventional cardiology medical director Dr. Paul Underwood said. “Our hope is that these ‘real-world’ results from the PLATINUM Diversity study will help clinicians, researchers and advocates understand the existing challenges so that we can work collaboratively to close the gender, race and ethnicity gap when treating cardiovascular disease.”
